Dioun, S., Chen, L., De Meritens, A. B., St. Clair, C. M., Hou, J. Y., Khoury-Collado, F., Pua, T., Hershman, D. L., & Wright, J. D. (2024). Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecologic Oncology, 182, 70–74. https://doi.org/10.1016/j.ygyno.2023.12.027
Subjects:
DNA Mismatch Repair
(MeSH)
Endometrial Neoplasms
(MeSH)
Phenylurea Compounds
(MeSH)
Quinolines
(MeSH)
Publication Type:
Article
Unique ID:
10.1016/j.ygyno.2023.12.027
PMID:
Journal:
Publication Date:
Data Source:
PubMed